In the last trading session, 1.1 million Leap Therapeutics Inc (NASDAQ:LPTX) shares changed hands as the company’s beta touched 0.12. With the company’s per share price at $0.56 changed hands at $0.04 or 7.86% during last session, the market valuation stood at $21.46M. LPTX’s last price was a discount, traded about -755.36% off its 52-week high of $4.79. The share price had its 52-week low at $0.51, which suggests the last value was 8.93% up since then. When we look at Leap Therapeutics Inc’s average trading volume, we note the 10-day average is 2.39 million shares, with the 3-month average coming to 683.35K.
Analysts gave the Leap Therapeutics Inc (LPTX) stock a consensus recommendation rating of Buy, calculated at a mean rating of 2.00. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended LPTX as a Hold, 3 felt it is a Buy and 0 rated the stock as Underweight. Leap Therapeutics Inc’s EPS for the current quarter is expected to be -0.38.
Leap Therapeutics Inc (NASDAQ:LPTX) trade information
Instantly LPTX was in green as seen at the end of in last trading. With action -73.95%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -80.52%, with the 5-day performance at -73.95% in the red. However, in the 30-day time frame, Leap Therapeutics Inc (NASDAQ:LPTX) is -80.82% down. Looking at the short shares, we see there were 1.01 million shares sold at short interest cover period of 2.68 days.
The consensus price target for the stock as assigned by Wall Street analysts is 5.5, meaning bulls need an upside of 89.82% from its current market value. According to analyst projections, LPTX’s forecast low is 5.5 with 5.5 as the target high. To hit the forecast high, the stock’s price needs a -882.14% plunge from its current level, while the stock would need to soar -882.14% for it to hit the projected low.
Leap Therapeutics Inc (LPTX) estimates and forecasts
Data shows that the Leap Therapeutics Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -73.83% over the past 6 months, a 53.77% in annual growth rate that is considerably higher than the industry average of 15.90%.
According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 28.36%. The 2025 estimates are for Leap Therapeutics Inc earnings to increase by 53.39%.
LPTX Dividends
Leap Therapeutics Inc is expected to release its next quarterly earnings report in March.
Leap Therapeutics Inc (NASDAQ:LPTX)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 17.29% of Leap Therapeutics Inc shares while 40.30% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 48.73%.
Among Mutual Funds, the top two as of Sep 30, 2024 were Simplify Exchange Traded Fds-Health Care ETF and Vanguard Total Stock Market Index Fund . With 1.06 shares estimated at $0.59 million under it, the former controlled 2.76% of total outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held about 1.97% of the shares, roughly 754.74 shares worth around $0.42 million.
